Careers  |  Sign In  |  Register  |   Twitter

Amgen Meets Study Goals for New Cholesterol-Lowering Drug

Current cholesterol-lowering drugs are mostly in the class of statins, but now Amgen Inc. has opened the door to a new class of drugs, Bloomberg News reports. Their new cholesterol drug, evolocumab, which targets PCSK9, a protein associated with low density lipoprotein (LDL) or “bad” cholesterol, has met its 5th late-stage study goals. “That puts Amgen, the world’s largest biotechnology company by revenue, ahead by six months to a year of its closest rival in the drug class, a compound being developed by Sanofi (SAN) and Regeneron Pharmaceuticals Inc. (REGN).” It is estimated that evolocumab can generate up t0 $1 billion in sales in 2018.

Read the article published by Bloomberg News.